Ideal for: HER2+ studies, ER- studies, AR inhibitors
The growing incidence of HER2 and Androgen Receptor positive (HER2+ and AR+) breast cancers has resulted in the need for relevant in vivo tumor models. Although typically associated with the growth of prostate cancer, recent studies reveal that AR is more widely expressed than estrogen receptor (ER) or progesterone receptor (PR) in breast cancer. AR expression occurs in 77% of the breast cancer with 88% being ER+, 59% HER2+, and 32% triple negative breast (TNBC) expressing AR respectively. shRNA and anti-AR compounds inhibit the growth of the HCC1954 breast cancer model demonstrating its utility in studying AR inhibition in the context of a HER2+ breast cancer (1).
HCC1954 is positive for Androgen Receptor (AR) and the epithelial cell specific marker Epithelial Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR). MCC1954 is HER2+ which is overexpressed in ELISA assays.
- He et a. (2017) Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Sci. Reports. 7:14584.
Enabling Case Study: HCC1954 tumor kinetics inOncoRat
OncoRat demonstrated a 100% engraftment rate for the HCC1954 xenograft model, providing an ideal host for HCC1954 tumor biology.
OncoRat HCC1954 products & services
- Xenograft efficacy studies, including collection of blood, tissues and tumor for ADME, PK/PD and analysis.
- OncoRats off-the-shelf for engraftment at the customers facility